The cytokine/chemokine pattern in the bone marrow environment of multiple myeloma patients

Experimental Hematology

Volumn 38, Issue 10, 2010, Pages 860-867

  Cao, Yanran ^a   Luetkens, Tim ^a   Kobold, Sebastian ^a   Hildebrandt, York ^a   Gordic, Maja ^a   Lajmi, Nesrine ^a   Meyer, Sabrina ^a   Bartels, Katrin ^a   Zander, Axel R ^a   Bokemeyer, Carsten ^a   Kröger, Nicolaus ^a   Atanackovic, Djordje ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; CXCL9 CHEMOKINE; CYCLOSPORIN A; CYTOKINE; EOTAXIN; EPIDERMAL GROWTH FACTOR; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GROWTH FACTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 12P40; INTERLEUKIN 12P70; INTERLEUKIN 13; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 22; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; METHOTREXATE; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; SCATTER FACTOR; THYMOCYTE ANTIBODY;

ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BLOOD ANALYSIS; BONE MARROW; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; MALE; MULTIPLE MYELOMA; MYELOMA CELL; PRIORITY JOURNAL;

BONE MARROW; CELL LINE, TUMOR; CHEMOKINES; CULTURE MEDIA, CONDITIONED; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GRAFT VS HOST DISEASE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PROGNOSIS; STEM CELL TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS;

EID: 77956581743     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2010.06.012     Document Type: Article

References (57)

1. Dispenzieri A., Lacy M.Q., Greipp P.R. Multiple myeloma. Wintrobe's Clinical Hematology 2004, 2583-2636. Lippincott Williams & Wilkins, Philadelphia. 11th ed. J.P. Greer, J. Foerster, J.N. Lukens, G.M. Rodgers, F. Paraskevas, B. Glader (Eds.).
2. Aggarwal R., Ghobrial I.M., Roodman G.D. Chemokines in multiple myeloma. Exp Hematol 2006, 34:1289-1295.
3. Kyle R.A., Rajkumar S.V. Multiple myeloma. N Engl J Med 2004, 351:1860-1873.
4. Higman M.A., Vogelsang G.B. Chronic graft versus host disease. Br J Haematol 2004, 125:435-454.
5. Barrett A.J., Rezvani K., Solomon S., et al. New developments in allotransplant immunology. Hematology Am Soc Hematol Educ Program 2003, 350-371.
6. Sherer Y., Shoenfeld Y. Autoimmune diseases and autoimmunity post-bone marrow transplantation. Bone Marrow Transplant 1998, 22:873-881.
7. Wood K.J., Sakaguchi S. Regulatory T cells in transplantation tolerance. Nat Rev Immunol 2003, 3:199-210.
8. Zorn E. CD4+CD25+ regulatory T cells in human hematopoietic cell transplantation. Semin Cancer Biol 2006, 16:150-159.
9. Shindo T., Ishikawa T., Fukunaga A., Hori T., Uchiyama T. Growth and differentiation advantages of CD4+ OX40+ T cells from allogeneic hematopoietic stem cell transplantation recipients. Biol Blood Marrow Transplant 2008, 14:268-281.
10. O'Shea J.J., Ma A., Lipsky P. Cytokines and autoimmunity. Nat Rev Immunol 2002, 2:37-45.
11. Salomon B., Bluestone J.A. Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu Rev Immunol 2001, 19:225-252.
12. Atanackovic D., Cao Y., Kim J.W., et al. The local cytokine and chemokine milieu within malignant effusions. Tumour Biol 2008, 29:93-104.
13. Glucksberg H., Storb R., Fefer A., et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974, 18:295-304.
14. Greipp P.R., San Miguel J., Durie B.G., et al. International staging system for multiple myeloma. J Clin Oncol 2005, 23:3412-3420.
15. Blade J., Samson D., Reece D., et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998, 102:1115-1123.
16. Hallek M., Bergsagel P.L., Anderson K.C. Multiple myeloma: increasing evidence for a multistep transformation process. Blood 1998, 91:3-21.
17. Van Riet I. Homing mechanisms of myeloma cells. Pathol Biol (Paris) 1999, 47:98-108.
18. Arendt B.K., Velazquez-Dones A., Tschumper R.C., et al. Interleukin 6 induces monocyte chemoattractant protein-1 expression in myeloma cells. Leukemia 2002, 16:2142-2147.
19. Biswas P., Delfanti F., Bernasconi S., et al. Interleukin-6 induces monocyte chemotactic protein-1 in peripheral blood mononuclear cells and in the U937 cell line. Blood 1998, 91:258-265.
20. Garrett I.R., Durie B.G., Nedwin G.E., et al. Production of lymphotoxin, a bone-resorbing cytokine, by cultured human myeloma cells. N Engl J Med 1987, 317:526-532.
21. Giuliani N., Lisignoli G., Colla S., et al. CC-Chemokine ligand 20/macrophage inflammatory protein-3alpha and CC-chemokine receptor 6 are overexpressed in myeloma microenvironment related to osteolytic bone lesions. Cancer Res 2008, 68:6840-6850.
22. Kawano M., Hirano T., Matsuda T., et al. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature 1988, 332:83-85.
23. Kroning H., Tager M., Thiel U., et al. Overproduction of IL-7, IL-10 and TGF-beta 1 in multiple myeloma. Acta Haematol 1997, 98:116-118.
24. Lacy M.Q., Donovan K.A., Heimbach J.K., Ahmann G.J., Lust J.A. Comparison of interleukin-1 beta expression by in situ hybridization in monoclonal gammopathy of undetermined significance and multiple myeloma. Blood 1999, 93:300-305.
25. Lee J.W., Chung H.Y., Ehrlich L.A., et al. IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells. Blood 2004, 103:2308-2315.
26. Pellegrino A., Antonaci F., Russo F., et al. CXCR3-binding chemokines in multiple myeloma. Cancer Lett 2004, 207:221-227.
27. Pellegrino A., Ria R., Di Pietro G., et al. Bone marrow endothelial cells in multiple myeloma secrete CXC-chemokines that mediate interactions with plasma cells. Br J Haematol 2005, 129:248-256.
28. Podar K., Tai Y.T., Davies F.E., et al. Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. Blood 2001, 98:428-435.
29. Podar K., Tai Y.T., Lin B.K., et al. Vascular endothelial growth factor-induced migration of multiple myeloma cells is associated with beta 1 integrin- and phosphatidylinositol 3-kinase-dependent PKC alpha activation. J Biol Chem 2002, 277:7875-7881.
30. Vacca A., Ribatti D., Roccaro A.M., Ria R., Palermo L., Dammacco F. Bone marrow angiogenesis and plasma cell angiogenic and invasive potential in patients with active multiple myeloma. Acta Haematol 2001, 106:162-169.
31. Vande Broek I., Asosingh K., Vanderkerken K., Straetmans N., Van Camp B., Van Riet I. Chemokine receptor CCR2 is expressed by human multiple myeloma cells and mediates migration to bone marrow stromal cell-produced monocyte chemotactic proteins MCP-1, -2 and -3. Br J Cancer 2003, 88:855-862.
32. Zhong H., Han B., Tourkova I.L., et al. Low-dose paclitaxel prior to intratumoral dendritic cell vaccine modulates intratumoral cytokine network and lung cancer growth. Clin Cancer Res 2007, 13:5455-5462.
33. Zlotnik A. Chemokines and cancer. Int J Cancer 2006, 119:2026-2029.
34. Ohshima K., Akaiwa M., Umeshita R., Suzumiya J., Izuhara K., Kikuchi M. Interleukin-13 and interleukin-13 receptor in Hodgkin's disease: possible autocrine mechanism and involvement in fibrosis. Histopathology 2001, 38:368-375.
35. Ellis M.J., Jenkins S., Hanfelt J., et al. Insulin-like growth factors in human breast cancer. Breast Cancer Res Treat 1998, 52:175-184.
36. Shurin M.R., Shurin G.V., Lokshin A., et al. Intratumoral cytokines/chemokines/growth factors and tumor infiltrating dendritic cells: friends or enemies?. Cancer Metastasis Rev 2006, 25:333-356.
37. Gu Z.J., Costes V., Lu Z.Y., et al. Interleukin-10 is a growth factor for human myeloma cells by induction of an oncostatin M autocrine loop. Blood 1996, 88:3972-3986.
38. Zdzisinska B., Bojarska-Junak A., Dmoszynska A., Kandefer-Szerszen M. Abnormal cytokine production by bone marrow stromal cells of multiple myeloma patients in response to RPMI8226 myeloma cells. Arch Immunol Ther Exp (Warsz) 2008, 56:207-221.
39. Niida S., Kaku M., Amano H., et al. Vascular endothelial growth factor can substitute for macrophage colony-stimulating factor in the support of osteoclastic bone resorption. J Exp Med 1999, 190:293-298.
40. Raman D., Baugher P.J., Thu Y.M., Richmond A. Role of chemokines in tumor growth. Cancer Lett 2007, 256:137-165.
41. Tanaka Y., Abe M., Hiasa M., et al. Myeloma cell-osteoclast interaction enhances angiogenesis together with bone resorption: a role for vascular endothelial cell growth factor and osteopontin. Clin Cancer Res 2007, 13:816-823.
42. Pellegrino A., Vacca A., Scavelli C., Dammacco F. [Chemokines and tumors]. Recent Prog Med 2002, 93:642-654.
43. Alexandrakis M.G., Passam F.H., Kyriakou D.S., et al. Serum level of interleukin-16 in multiple myeloma patients and its relationship to disease activity. Am J Hematol 2004, 75:101-106.
44. Lauta V.M. A review of the cytokine network in multiple myeloma: diagnostic, prognostic, and therapeutic implications. Cancer 2003, 97:2440-2452.
45. Rand T.H., Cruikshank W.W., Center D.M., Weller P.F. CD4-mediated stimulation of human eosinophils: lymphocyte chemoattractant factor and other CD4-binding ligands elicit eosinophil migration. J Exp Med 1991, 173:1521-1528.
46. Seidel C., Borset M., Turesson I., Abildgaard N., Sundan A., Waage A. Elevated serum concentrations of hepatocyte growth factor in patients with multiple myeloma. The Nordic Myeloma Study Group. Blood 1998, 91:806-812.
47. Borset M., Seidel C., Hjorth-Hansen H., Waage A., Sundan A. The role of hepatocyte growth factor and its receptor c-Met in multiple myeloma and other blood malignancies. Leuk Lymphoma 1999, 32:249-256.
48. Derksen P.W., de Gorter D.J., Meijer H.P., et al. The hepatocyte growth factor/Met pathway controls proliferation and apoptosis in multiple myeloma. Leukemia 2003, 17:764-774.
49. Hov H., Holt R.U., Ro T.B., et al. A selective c-met inhibitor blocks an autocrine hepatocyte growth factor growth loop in ANBL-6 cells and prevents migration and adhesion of myeloma cells. Clin Cancer Res 2004, 10:6686-6694.
50. Goede V., Brogelli L., Ziche M., Augustin H.G. Induction of inflammatory angiogenesis by monocyte chemoattractant protein-1. Int J Cancer 1999, 82:765-770.
51. Center D.M., Kornfeld H., Cruikshank W.W. Interleukin 16 and its function as a CD4 ligand. Immunol Today 1996, 17:476-481.
52. Hauser A.E., Debes G.F., Arce S., et al. Chemotactic responsiveness toward ligands for CXCR3 and CXCR4 is regulated on plasma blasts during the time course of a memory immune response. J Immunol 2002, 169:1277-1282.
53. Moller C., Stromberg T., Juremalm M., Nilsson K., Nilsson G. Expression and function of chemokine receptors in human multiple myeloma. Leukemia 2003, 17:203-210.
54. Moser K., Muehlinghaus G., Manz R., et al. Long-lived plasma cells in immunity and immunopathology. Immunol Lett 2006, 103:83-85.
55. Giuliani N., Bonomini S., Romagnani P., et al. CXCR3 and its binding chemokines in myeloma cells: expression of isoforms and potential relationships with myeloma cell proliferation and survival. Haematologica 2006, 91:1489-1497.
56. Graft-vs.-host disease 2005, 143. Marcel Dekker, New York, NY. 3rd ed. J. Von, L.M. Ferrara, K.R. Cooke, H.J. Deeg (Eds.).
57. Daneshpouy M., Socie G., Lemann M., Rivet J., Gluckman E., Janin A. Activated eosinophils in upper gastrointestinal tract of patients with graft-versus-host disease. Blood 2002, 99:3033-3040.